A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study

Khalid A. Jadoon,1 Garry D. Tan,2 and Saoirse E. O’Sullivan1

1Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, United Kingdom. 2The NIHR Oxford Biomedical Research Centre, Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.

Introduction

Epidemiological studies have shown a positive relationship between long-term stress and the development of cardiovascular disease (1). Factors like social isolation, low socioeconomic status, depression, stressful family and work life, and anxiety are associated with an increased risk of the development and accelerated progression of existing cardiovascular disease. Current European guidelines on the prevention of cardiovascular disease have emphasized the importance of tackling these factors (2). Mental stress induces myocardial ischaemia in patients with stable coronary artery disease, and this appears to be mediated by adrenal release of catecholamines (3).

Cannabinoids (CBs) are compounds that bind to CB receptors or are structurally similar to compounds that bind to CB receptors. They include endogenously produced compounds (called endocannabinoids), synthetic compounds and phytocannabinoids obtained from the Cannabis sativa plant. There are over 80 known types of phytocannabinoids, the most widely studied of which is Δ⁹-tetrahydrocannabinol (Δ⁹-THC or THC), which is responsible for the psychoactive properties of cannabis (4). The other major phytocannabinoid is cannabidiol (CBD), which does not have psychoactive properties. CBD is currently the focus of much research due to its potential in a number of therapeutic areas, as it has been shown to have antiinflammatory, anticonvulsant, antioxidant, anxiolytic, antinausea, and antipsychotic properties (5). A number of preclinical studies have also shown beneficial effects of CBD in a range of disorders of the cardiovascular system (6). A CBD/THC combination (Sativex/Nabiximols, GW Pharmaceuticals) is licensed for the treatment of spasticity in multiple sclerosis, and CBD alone (Epidiolex, GW Pharmaceuticals) has entered an expanded access program in children with intractable epilepsies (Dravet...
syndrome and Lennox-Gastaut syndrome). Epidiolex has also received orphan designation status for the treatment of neonatal hypoxia-ischaemic encephalopathy.

CBD has multiple desirable effects on the cardiovascular system. It attenuates high glucose–induced proinflammatory changes in human coronary artery endothelial cells (7) and myocardial dysfunction associated with animal models of diabetes (8), and it preserves endothelial integrity in diabetic retinal microvasculature (9). In vivo administration of CBD before cardiac ischemia and reperfusion also reduces ventricular arrhythmias and infarct size. CBD also causes both acute and time-dependent vasorelaxation in isolated arteries in rats and humans (10–12). There is also evidence from animal studies that CBD modulates the cardiovascular response to stress. Resstel and colleagues (13) showed in rats that i.p. injection of CBD (10 and 20 mg/kg, –30 min) reduced restraint stress–induced cardiovascular response and behavior. Both these effects were blocked by preadministration of WAY100635 (0.1 mg/kg), a 5-hydroxytryptamine 1A (5HT₁A) antagonist. These effects appear to be mediated centrally and involve the bed nucleus of the stria terminalis (BNST), a limbic structure that modulates neuroendocrine responses to acute stress (14).

Our recent systematic review showed us that there are no dedicated studies in humans to date, to our knowledge, looking at the effect of CBD on either resting cardiovascular measurement or on the responses to stress, with continuous monitoring of CV parameters (15). Therefore, the aim of the present study was to investigate whether CBD decreases the cardiovascular response to stress after the administration of a single dose of CBD (600 mg) in healthy volunteers, with the hypothesis that blood pressure would be reduced by CBD. Noninvasive cardiovascular measurements were used along with stress tests in the form of mental arithmetic, isometric exercise, and the cold pressor test.

Figure 1. Changes in resting cardiovascular parameters after a single dose (600 mg) of cannabidiol (CBD) in healthy volunteers (n = 9). The effects of placebo (closed square) and CBD (open square) on systolic blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), mean arterial blood pressure (MAP) (C), heart rate (HR) (D), stroke volume (SV) (E), cardiac output (CO) (F), ejection time (EJT) (G), total peripheral resistance (TPR) (H), and forearm blood flow (I), measured continuously over 2 hours after drug ingestion, except for forearm blood flow. Forearm blood was measured over a time period of 2 minutes just before the start and in between the stress tests. Dotted line denotes baseline values between the stress tests. Repeated measures 2-way ANOVA; mean ± SEM (*P < 0.05, **P < 0.01 using Bonferroni’s post-hoc analysis; + and # represent significant change in any parameter over time seen with placebo and CBD, respectively; denotes overall significant difference between 2 treatments).
### Mental arithmetic

<table>
<thead>
<tr>
<th>Subject</th>
<th>Systolic blood pressure</th>
<th>Diastolic blood pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Peak (25 s)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>CBD</td>
</tr>
<tr>
<td>1</td>
<td>132</td>
<td>112</td>
</tr>
<tr>
<td>2</td>
<td>106</td>
<td>115</td>
</tr>
<tr>
<td>3</td>
<td>130</td>
<td>139</td>
</tr>
<tr>
<td>4</td>
<td>119</td>
<td>118</td>
</tr>
<tr>
<td>5</td>
<td>124</td>
<td>123</td>
</tr>
<tr>
<td>6</td>
<td>131</td>
<td>114</td>
</tr>
<tr>
<td>7</td>
<td>140</td>
<td>130</td>
</tr>
<tr>
<td>8</td>
<td>125</td>
<td>126</td>
</tr>
<tr>
<td>9</td>
<td>138</td>
<td>129</td>
</tr>
</tbody>
</table>

### Isometric exercise

<table>
<thead>
<tr>
<th>Subject</th>
<th>Systolic blood pressure</th>
<th>Diastolic blood pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Peak (2 min)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>CBD</td>
</tr>
<tr>
<td>1</td>
<td>127</td>
<td>111</td>
</tr>
<tr>
<td>2</td>
<td>107</td>
<td>112</td>
</tr>
<tr>
<td>3</td>
<td>128</td>
<td>121</td>
</tr>
<tr>
<td>4</td>
<td>128</td>
<td>117</td>
</tr>
<tr>
<td>5</td>
<td>118</td>
<td>119</td>
</tr>
<tr>
<td>6</td>
<td>133</td>
<td>114</td>
</tr>
<tr>
<td>7</td>
<td>142</td>
<td>131</td>
</tr>
<tr>
<td>8</td>
<td>131</td>
<td>121</td>
</tr>
<tr>
<td>9</td>
<td>139</td>
<td>125</td>
</tr>
</tbody>
</table>

### Cold pressor test

<table>
<thead>
<tr>
<th>Subject</th>
<th>Systolic blood pressure</th>
<th>Diastolic blood pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Peak (2 min)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>CBD</td>
</tr>
<tr>
<td>1</td>
<td>114</td>
<td>113</td>
</tr>
<tr>
<td>2</td>
<td>116</td>
<td>115</td>
</tr>
<tr>
<td>3</td>
<td>133</td>
<td>128</td>
</tr>
<tr>
<td>4</td>
<td>127</td>
<td>125</td>
</tr>
<tr>
<td>5</td>
<td>123</td>
<td>122</td>
</tr>
<tr>
<td>6</td>
<td>142</td>
<td>129</td>
</tr>
<tr>
<td>7</td>
<td>137</td>
<td>145</td>
</tr>
<tr>
<td>8</td>
<td>137</td>
<td>123</td>
</tr>
<tr>
<td>9</td>
<td>139</td>
<td>130</td>
</tr>
</tbody>
</table>

Figure 2. Individual systolic and diastolic blood pressure responses to all stress tests after a single dose (600 mg) of cannabidiol (CBD) or placebo in healthy volunteers (*n* = 9). Green color coding shows subjects who had a reduced (compared with placebo) blood pressure response to stress after taking CBD, and red color coding shows an increased blood pressure response to stress after taking CBD.

### Results

Ten male subjects were recruited, but 1 withdrew for personal reasons. The mean age, weight, and height of the volunteers were 23.7 ± 3.2 years, 77.5 ± 6.4 kg, and 178.6 ± 4.5 cm (mean ± SD).

*Effect of CBD on resting cardiovascular parameters.* CBD treatment reduced resting systolic blood pressure...
CLINICAL MEDICINE

SBP (mean difference –6 mmHg; 95% CI, –1 to –12, \( P < 0.05 \), Figure 1A). Although there was no overall difference in diastolic blood pressure (DBP) and mean arterial blood pressure (MAP) between the 2 groups, post-hoc analysis showed that both DBP and MAP were lower with CBD treatment (Figure 1B and C, respectively; \( P < 0.01 \)), particularly in the latter time points (120–160 min).

CBD treatment reduced resting stroke volume (SV; mean difference –8 ml; 95% CI, –2 to –14, \( P < 0.05 \), Figure 1E) and increased heart rate (HR), with significant difference in HR between CBD and placebo from an hour after ingestion of drug (Figure 1D, \( P < 0.05 \)). There was a decline in left ventricular ejection time (EJT) with both treatments (\( P < 0.05 \); Figure 1G), while cardiac output (CO) (Figure 1F) remained unchanged.

There was a trend toward reduction in total peripheral resistance (TPR, Figure 1H) with CBD in the latter half of the resting period, and a significant reduction in forearm skin blood flow before the start of the stress tests (Figure 1I; \( P < 0.01 \)).

**Effect of CBD on cardiovascular parameters mental stress.** The individual blood pressure responses of healthy volunteers to the stresses are presented in Figure 2, showing the average baseline systolic or diastolic blood pressure in the 4 minutes preceding the stress test, the peak response during stress, and the average recovery response in the 4 minutes after the stress test.

Mental stress test. Mental stress caused a rise in HR (\( P < 0.05 \); Figure 3D) and a decline in SV (\( P < 0.01 \); Figure 3E), which was seen in both the CBD and placebo groups. There was a rise in DBP (\( P < 0.05 \); Figure 3B) and a decline in EJT (\( P < 0.05 \); Figure 3G), seen only in those who had taken CBD.
Although overall, there was no difference in the cardiovascular parameters between the 2 treatments, post-hoc analysis showed that SBP (Figure 3A; \( P < 0.05 \) to \( < 0.0001 \)), DBP (Figure 3B; \( P < 0.05 \) to \( < 0.01 \)), and MAP (Figure 3C; \( P < 0.05 \) to \( < 0.0001 \)) were significantly lower in volunteers who had taken CBD, especially immediately after the stress test. Looking at the individual response to mental stress, 6 of 9 subjects had a lower SBP before or during the mental stress test, and 9 of 9 subject had a lower SBP in the recovery period after taking CBD (Figure 2). Five of 9 subjects had a lower DBP during the mental stress test, and 6 of 9 subject had a lower DBP in the recovery period after taking CBD (Figure 2).

CBD increased HR during the latter part of mental stress and in the poststress period (Figure 3D; \( P < 0.05 \) to \( < 0.0001 \)), with a corresponding decline in EJT (Figure 3G; \( P < 0.05 \) to \( < 0.0001 \)). Although CBD reduced SV (Figure 3E; \( P < 0.05 \) to \( < 0.0001 \)), there was no difference in CO between CBD and placebo (Figure 3F).

Compared with placebo, volunteers who had taken CBD had a lower TPR throughout and especially in the post–mental stress period (Figure 3H; \( P < 0.05 \) to \( < 0.0001 \)). Volunteers who had taken CBD also reduced forearm skin blood flow before and during the latter part of mental stress (Figure 3I; \( P < 0.05 \) to \( < 0.01 \)).

**Exercise stress test.** The isometric exercise stress caused a significant rise in the following parameters in both treatment groups; SBP (placebo \( P < 0.01 \), CBD \( P < 0.001 \); Figure 4A), DBP (placebo \( P < 0.01 \), CBD \( P < 0.0001 \); Figure 4B), MAP (placebo \( P < 0.01 \), CBD \( P < 0.0001 \); Figure 4C), and HR (placebo \( P < 0.05 \), CBD \( P < 0.001 \); Figure 4D).

**Figure 4.** Cardiovascular parameters in response to exercise stress after a single dose (600 mg) of cannabidiol (CBD) in healthy volunteers (\( n = 9 \)). The effects of placebo (closed square) and CBD (open square) on systolic blood pressure (SBP) (A), diastolic blood pressure (DBP) (B), mean arterial blood pressure (MAP) (C), heart rate (HR) (D), stroke volume (SV) (E), cardiac output (CO) (F), ejection time (EJT) (G), total peripheral resistance (TPR) (H), and forearm blood flow (I), measured continuously just before, during, and after isometric exercise test (dotted line denotes stress test period), except for forearm blood flow. Measurements for forearm blood flow were made over a 2-minute window just before, during, and after the stress test. Repeated measures 2-way ANOVA; mean ± SEM (*\( / \,*P < 0.05; **\( / \,**P < 0.01; ***\( / \,***P < 0.001; ****/####P < 0.0001 \) using Bonferroni post-hoc analysis; + and # denote significant change in a parameter during the stress period seen with placebo and CBD respectively).
Overall, CBD treatment reduced SBP (mean difference –5 mmHg; 95% CI, –1 to –10, \(P < 0.05\), Figure 4A) and MAP (mean difference –5 mmHg, 95% CI, –2 to –9, \(P < 0.05\), Figure 4C) during the exercise stress. Looking at the individual response to exercise stress, 6 of 9 subjects had a lower SBP during isometric exercise and 8 of 9 subjects had a lower SBP in the recovery period after taking CBD (Figure 2). Five of 9 subjects had a lower DBP during exercise, and 8 of 9 subject had a lower DBP in the recovery period after taking CBD (Figure 2).

Subjects who had taken CBD had increased HR (mean difference 10 bpm; 95% CI, 5–14, \(P < 0.01\), Figure 4D) and decreased SV (mean difference –13 ml; 95% CI, –4 to –22, \(P < 0.01\), Figure 4E) and EJT (mean difference –0.01 sec, 95% CI, –0.001 to –0.03, \(P < 0.05\), Figure 4G) during the exercise stress. There was no difference in CO during the exercise stress (Figure 4F).

A rise in forearm cutaneous blood flow in response to exercise (as would be expected) was only seen in volunteers who had taken placebo (\(P < 0.05\); Figure 4I). Post-hoc analysis showed significantly lower forearm skin blood flow in those who had taken CBD (Figure 4I; \(P < 0.01\) to < 0.0001), during the early and latter parts of the stress test. This was associated with reduced TPR (Figure 4H; \(P < 0.05\) to < 0.001) before, after, and in the latter half of exercise stress.

Cold stress test. The cold pressor test caused a rise in SBP (placebo \(P < 0.01\), CBD \(P < 0.05\); Figure 5A) and MAP (placebo \(P < 0.001\), CBD \(P < 0.05\); Figure 5C) in both groups and a rise in DBP only with placebo (\(P < 0.01\); Figure 5B). An equal rise in SBP and MAP was seen with both CBD and placebo in the first half of this stress test. However, while the blood pressure (SBP and MAP) continued to rise in the placebo group, it plateaued in volunteers who had taken CBD, and therefore both SBP and MAP were significantly...
lower in volunteers after CBD (mean difference –8 mmHg [95% CI, –4 to –12, \( P < 0.01 \)] and –6 mmHg [95% CI, –2 to –11, \( P < 0.01 \)]. Post-hoc analysis showed that DBP was also significantly lower in those who had taken CBD in the latter half of the stress period (Figure 5B; \( P < 0.001 \)).

Looking at the individual response to the cold pressor test, 8 of 9 subjects had a lower SBP during the cold stress and in the recovery period after taking CBD (Figure 2). Six of 9 subjects had a lower DBP during the cold pressor, and 7 of 9 subject had a lower DBP in the recovery period after taking CBD (Figure 2).

As before, HR was higher in volunteers who had taken CBD (mean difference 7 bpm; 95% CI: 2–13; \( P < 0.05 \); Figure 5D), and EJT was lower (mean difference -0.01 sec; 95% CI: 0 to –0.02; \( P < 0.05 \); Figure 5G). Sidak post-hoc analysis showed that SV was significantly lower with CBD throughout (Figure 5E; \( P < 0.05 \) to < 0.0001), but there was no decline in cardiac output (Figure 5F).

The cold pressor test caused a significant rise in TPR (as expected) in the placebo group only (Figure 5H; \( P < 0.01 \)) and rise in forearm skin blood flow with both CBD and placebo (Figure 5I; \( P < 0.05 \)). The overall trend was for lower TPR and forearm skin blood flow in those who had taken CBD, with post-hoc analysis showing a reduction in both just before and in the latter half of cold stress (Figure 5H [\( P < 0.05 \) to < 0.0001] and Figure 5I [\( P < 0.001 \)]).

**Discussion**

Based on preclinical evidence, the aim of this study was to test the hypothesis that CBD would reduce the cardiovascular response to stress in healthy volunteers. We found that resting blood pressure was lower after subjects had taken CBD and that CBD blunted the blood pressure response to stress, particularly in the pre- and poststress periods. Post-hoc analysis showed an overall trend of lower S BP , MAP, DBP, SV, TPR, forearm skin blood flow, and left ventricular E JT and a higher HR in subjects who had taken CBD. These hemodynamic changes should be considered for people taking CBD and suggest that further research is warranted to establish whether CBD has any role in the treatment of cardiovascular disorders.

We have shown for the first time that to our knowledge that, in humans, acute administration of CBD reduces resting blood pressure, with a lower stroke volume and a higher heart rate. This response may be secondary to the known anxiolytic properties of CBD (16) and may account for the lack of anticipatory rise in blood pressure seen with placebo. These findings are in contrast to previous studies in humans, where CBD at the same dose did not affect baseline cardiovascular parameters (17–19), although changes in the cardiovascular system were not the primary outcome of these studies. In the present study, CV parameters were measured continuously, while in previous studies, monitoring for S BP , DBP , and HR were performed manually at only 1, 2, or 3 hours after drug delivery. Additionally, our subjects were cannabis naive, while the subjects of other studies had used cannabis in the past. Since tolerance may develop to the hemodynamic response to CBs in humans, this may explain the differences between studies.

THC, the major psychoactive component of cannabis, is known to cause tachycardia and orthostatic hypotension in humans (20), a hemodynamic response similar to that observed to CBD in the present study. THC is a partial agonist at both CB\(_1\) and CB\(_2\) receptors (21), and the effects of THC on heart rate are mediated through CB\(_1\) receptors (20). CBD does not bind with any great affinity to CB\(_1\), but it can interact indirectly by augmenting CB\(_1\) receptors’ constitutional activity or endocannabinoid tone, the so called indirect agonism (22). We recently showed that CBD also causes endothelium-dependent vasorelaxation in isolated human mesenteric arteries through CB\(_1\) activation (11). Therefore, it is possible that the changes in hemodynamics brought about by CBD are mediated through CB\(_1\).

CBD may cause sympathoinhibition (through CB\(_1\), or some other mechanism), thereby preventing an increase in blood pressure and cardiac output, causing a compensatory rise in heart rate to maintain cardiac output. Indeed, the changes in SBP preceded any changes in HR. Another possibility is that CBD inhibits cardiac vagal tone, thereby increasing heart rate (despite any potential sympathoinhibition). A recent study in male Sprague-Dawley rats showed that GPR18 activation in the rostral ventrolateral medulla (RVL M) by abnormal CBD (Abn-CBD) resulted in reduced blood pressure and increased heart rate (23) (similar to that observed in the present study). The same study showed that pretreatment with atropine and propranolol fully abrogated the HR response, suggesting a role for the autonomic nervous system. CBD is a weak partial agonist at GPR18 (24).

*Effect of CBD on cardiovascular parameters in response to mental stress.* Mental arithmetic has been shown to cause a rise in MAP and muscle sympathetic nerve activity (MSNA) (25) and vasodilatation in forearm skeletal muscle (26). In our study, none of the cardiovascular parameters other than HR,
β-lactation, which could be a result of general sympathoinhibition or a specific effect at the 2 adrenoceptors. CB1 receptors, leading to desensitisation of β2 adrenoceptors and CB1 receptors overlaps in many tissues, including in the β-cell. Data analysis was blinded.

The tissue distribution of β2 adrenoceptors and CB1 receptors overlaps in many tissues, including in the β-cell. Allocation was decided by a coin toss, and block randomization was employed by S.E. O’Sullivan, who assigned participants. K.A. Jadoon carried out all study visits, the School of Medicine, Royal Derby Hospital. The study was a randomized, crossover design with each subject given CBD (BN: K12067A) or placebo (both gifts from GW Pharmaceuticals) in a capsule in a double-blind fashion, with a minimum time interval of at least 48 hours (range 3–16 days), taking place at the Division of Medical Sciences, School of Medicine, Royal Derby Hospital. Allocation was decided by a coin toss, and block randomization was employed by S.E. O’Sullivan, who assigned participants. K.A. Jadoon carried out all study visits, and data analysis was blinded.

Study design. The study was a randomized, crossover design with each subject given CBD (BN: K12067A) or placebo (both gifts from GW Pharmaceuticals) in a capsule in a double-blind fashion, with a minimum time interval of at least 48 hours (range 3–16 days), taking place at the Division of Medical Sciences, School of Medicine, Royal Derby Hospital. Allocation was decided by a coin toss, and block randomization was employed by S.E. O’Sullivan, who assigned participants. K.A. Jadoon carried out all study visits, and data analysis was blinded.
During an initial visit, subjects were familiarized with the stress tests and with noninvasive cardiovascular (CVS) monitoring, and an electrocardiogram (ECG) was done to rule out any preexisting cardiac conditions. Subjects were advised to fast overnight, to avoid beverages containing caffeine or alcohol, and to avoid strenuous exercise for 24 hours before each of the 2 study visits. Two hours after CBD/placebo was administered, subjects performed various stress tests (36). Noninvasive cardiovascular monitoring using Finometer and laser Doppler flowmetry was carried out during the 2 hours to assess changes in baseline parameters and during the stress test periods.

**Visit days.** Upon arrival, subjects were rested for 10–15 minutes, and their baseline blood pressure and heart rate were recorded using a digital blood pressure (BP) monitor. Participants were given a standardized breakfast, and 15 minutes later, they were given either oral CBD (600 mg) or placebo in a double-blind fashion. This is a dose known to cause anxiolytic effects in humans and is comparable with what is used clinically (19, 37–39). Study medication consisted of capsules containing either 100 mg of CBD or excipients, which were a gift from GW Pharmaceuticals. There was no difference between the 2 formulations in color, taste, or smell.

Two hours afterward, subjects were asked to perform the stress tests (36). Timing of the tests was chosen to coincide with peak plasma levels for CBD (18). All the experiments were performed in a sitting position under ambient temperature conditions. Maximum voluntary contraction for the isometric hand grip test was assessed for each subject prior to administering study medication.

After administration of CBD or placebo, subjects remained seated, either doing nothing, reading, or using a computer. During this time, subjects were connected to a calibrated Finometer (Finapres Medical Systems), which uses a finger-clamp method to detect beat-to-beat changes in digital arterial diameter using an infrared photoplethysmograph (40). The Finometer gives a continuous signal of beat-to-beat changes in blood pressure and blood flow, and it uses this signal to derive other parameters, including systolic, diastolic, and mean blood pressure; interbeat interval; heart rate and left ventricular ejection time; stroke volume; cardiac output; and systemic peripheral resistance. Baseline cardiovascular data was recorded for 2 hours following administration of CBD or placebo. Forearm blood flow was measured using a calibrated laser Doppler flowmeter (Perimed) (41). For each recording, 5 images of microcirculation were taken, over an area 19 mm × 19 mm, using the upper third of the left forearm under high resolution. After 2 hours, subjects underwent the cardiovascular stress tests in the following order: mental arithmetic, isometric exercise, and cold pressor test.

The mental arithmetic test consisted of calculating a sum every 2 second for 2 minutes. Subjects were seated in front of a computer screen, and a PowerPoint presentation delivered a slide with a simple mathematical sum of a 3-digit number minus a smaller number (e.g., 317 – 9, 212 – 11, 185 – 7) every 2 seconds; the subject had to give the answer verbally. In the isometric exercise stress test, using a dynamometer, hand-grip was maintained at 30% of maximum voluntary contraction (MVC) for 2 min. For the cold pressor test, subjects immersed their left foot (up to ankle) in ice slush (temperature 4°C–6°C) for 2 minutes. Cardiovascular parameters were measured continuously using the Finometer, while skin blood flow measurements were taken just before, during, and 5 minutes after each test. Each stress test lasted for 2 minutes, and there was a recovery period of at least 10 minutes.

**Statistics.** Data were analyzed using repeated measures ANOVA to determine the effect of treatment and time on different variables using GraphPad PRISM version 6.02. Level of significance was set at $\alpha = 0.05$ and values presented as mean ± SEM. Sidak’s post-hoc test was used to see treatment affect at various time points. Data were not unblinded until after statistical analysis.

**Study approval.** Ten healthy young male volunteers, mean age 24 years (range 19–29), with no underlying cardiovascular or metabolic disorders, were recruited for this study, which was approved by the University of Nottingham Faculty of Medicine Ethics Committee (study reference E18102012). Written informed consent was obtained according to the Declaration of Helsinki. Exclusion criteria included any significant cardiovascular or metabolic disorder or use of any medication. All the volunteers were nonsmokers and had taken no prescribed or over-the-counter medication within a week prior to randomization. No volunteers had ever used cannabis.

**Author contributions**

KAJ helped with study design, researched data, wrote the manuscript, and reviewed/edited the manuscript. GDT reviewed/edited the manuscript. SEO was involved in study design and reviewed/edited the manuscript.
Acknowledgments

GT is supported by the NIHR Oxford Biomedical Research Centre Programme. The views expressed are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health.

Address correspondence to: Saoirse E. O’Sullivan, Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital Centre, Uttoxeter Road, Derby DE22 3DT, United Kingdom. Phone: 44.1332.724701; E-mail: mbzso@nottingham.ac.uk.


